Aqua Bio Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Aqua Bio Technology şirketinin toplam hissedar öz sermayesi NOK7.7M ve toplam borcu NOK20.3M olup, bu da borç-öz sermaye oranını 264.7% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla NOK66.7M ve NOK59.0M dir.

Anahtar bilgiler

264.7%

Borç/özkaynak oranı

NOK 20.33m

Borç

Faiz karşılama oranı	n/a
Nakit	NOK 727.44k
Eşitlik	NOK 7.68m
Toplam yükümlülükler	NOK 58.99m
Toplam varlıklar	NOK 66.67m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More Shares

Jan 20

Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?

Dec 30

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ABTEC 'nin kısa vadeli varlıkları ( NOK11.1M ) kısa vadeli yükümlülüklerini ( NOK33.6M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: ABTEC 'un kısa vadeli varlıkları ( NOK11.1M ) uzun vadeli yükümlülüklerini ( NOK25.4M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ABTEC 'nin net borç/öz sermaye oranı ( 255.2% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: ABTEC şirketinin borç/öz sermaye oranı son 5 yılda 1.7% seviyesinden 264.7% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ABTEC şirketinin mevcut serbest nakit akışına dayanarak yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Tahmini Nakit Akışı: ABTEC tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Aqua Bio Technology Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 0/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Aqua Bio Technology ASA Announces CEO Changes, Effective December 1, 2024

Aqua Bio Technology ASA (OB:ABTEC) completed the acquisition of 3d Innovation Nordic As from Coc Invest AS.

New major risk - Financial data availability

New major risk - Share price stability

Aqua Bio Technology ASA to Report Q4, 2024 Results on Feb 12, 2025

New minor risk - Financial data availability

Aqua Bio Technology ASA has filed a Follow-on Equity Offering in the amount of NOK 5 million.

Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 12.457015 million.

Aqua Bio Technology ASA (OB:ABTEC) entered into a share purchase agreement to acquire Cover Brands As from Medvind Holding As for NOK 16.5 million.

New major risk - Shareholder dilution

Aqua Bio Technology Asa Receives European Patent for Use of Chaga in Cosmetic Formulations

New minor risk - Shareholder dilution

Aqua Bio Technology ASA announced that it has received NOK 75.999999 million in funding

New major risk - Share price stability

Aqua Bio Technology ASA announced that it expects to receive NOK 76 million in funding

Aqua Bio Technology ASA (OB:ABTEC) entered into a binding agreement in principle to acquire SkinTeam Norge AS for NOK 45 million.

Aqua Bio Technology ASA Provides Earnings Guidance for the Full Year 2023

Aqua Bio Technology ASA, Annual General Meeting, Apr 28, 2023

No independent directors

Aqua Bio Technology ASA (OB:ABT) acquired Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

Aqua Bio Technology ASA (OB:ABT) entered into a binding term sheet to acquire Cosmed Beauty AS and Ultrabody AB from Varming Holding As.

No independent directors

Aqua Bio Technology ASA Announces Hydrafacial Launches Products Containing Aquabeautine XL in the UK

Chief Executive Officer recently bought kr55k worth of stock

Insider recently sold kr1.9m worth of stock

Director recently bought kr57m worth of stock

Aqua Bio Technology ASA Announces Strategic Partnership with DCP Dermoscience

Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Moana Active Skincare Limited for New Zealand and Australia

Aqua Bio Technology ASA Signs an Distribution Agreement with Galaxa Pharma Aps

Aqua Bio Technology ASA Signs Exclusive Distribution Agreement with Cosmed Beauty AS

Aqua Bio Technology ASA to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr9.20

The Director of Aqua Bio Technology ASA (OB:ABT), Roger Hofseth, Just Bought A Few More Shares

Director recently bought kr141k worth of stock

Have Insiders Been Buying Aqua Bio Technology ASA (OB:ABT) Shares?

Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies of 6 Products from the Product Series Balance & Vitality

Aqua Bio Technology Asa: Hydrafacial Has Entered into Partnership with Restorsea - Conversion Lab Launches Veritas Md Platform

Aqua Bio Technology ASA (OB:ABT) completed the acquisition of distribution of Moana Skincare from Limited Liability Company Management Company AB GROUP.

Aqua Bio Technology ASA Expects to Enter into Three-Year Agreement for the Distribution of Moana Products in New Zealand and Australia

Aqua Bio Technology ASA Announces Completion and Approval of Safety Studies by Nordic Beauty

Aqua Bio Technology ASA has completed a Follow-on Equity Offering in the amount of NOK 2.526 million.

New 90-day high - kr8.35

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin